Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CytomX TherapeuticsCTMX -5.49%36 Equity-to-Asset is 0.89 as of Mar. 2026, which is 424% above its 10-year median of 0.17. GuruFocus rates CTMX with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,416 Biotechnology companies, CytomX Therapeutics ranks better than 81.5% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. CytomX Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $319.94 Mil. CytomX Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $359.36 Mil.
Therefore, CytomX Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.89.
The historical rank and industry rank for CytomX Therapeutics's Equity-to-Asset or its related term are showing as below:
CTMX'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.41 Med: 0.17 Max: 0.89
Current: 0.89
During the past 13 years, the highest Equity to Asset Ratio of CytomX Therapeutics was 0.89. The lowest was -0.41. And the median was 0.17.
CTMX's Equity-to-Asset is ranked better than 81.5% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs CTMX: 0.89
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
CytomX Therapeutics Equity-to-Asset Related Terms
CytomX Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for CytomX Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTMX vs BBOT, OMER, STTK: Equity-to-Asset Comparison
For the Biotechnology subindustry, CytomX Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytomX Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where CytomX Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
CytomX Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytomX Therapeutics (CTMX) has a Equity-to-Asset of 0.89 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CytomX Therapeutics and its competitors. This is 424% above median its historical median of 0.17. According to the industry distribution chart, CytomX Therapeutics ranks #262 out of 1416 companies in the Biotechnology industry, placing it in the top 18.5%.
Is CytomX Therapeutics' Equity-to-Asset too high?
CytomX Therapeutics' current Equity-to-Asset of 0.89 is 424% above median its 10-year median of 0.17. The Biotechnology industry median Equity-to-Asset is 0.68. CytomX Therapeutics' value of 0.89 is 30.9% above this industry median. Based on the distribution chart, CytomX Therapeutics ranks #262 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CytomX Therapeutics has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CytomX Therapeutics' Equity-to-Asset compare to BBOT and OMER?
According to the Biotechnology industry distribution chart, CytomX Therapeutics ranks #262 out of 1416 companies for Equity-to-Asset. This places CytomX Therapeutics in the top 19% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. CytomX Therapeutics' value of 0.89 is 30.9% above this benchmark. While the company's 10-year median is 0.17 vs. the industry median of 0.68, CytomX Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CytomX Therapeutics's current Equity-to-Asset of 0.89 is 30.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CytomX Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytomX Therapeutics's current Equity-to-Asset is 0.89, which is 424% above median its own 10-year median of 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytomX Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CytomX Therapeutics (CTMX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $3.10 — trading 1007.1% above its estimated fair value. The current Equity-to-Asset is 0.89, which is 424% above median its 10-year median of 0.17 and 30.9% above the Biotechnology industry median of 0.68. CytomX Therapeutics' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For CytomX Therapeutics (CTMX), the current Equity-to-Asset is 0.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CytomX Therapeutics (CTMX) Overvalued in 2026?
Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued.
The current stock price of $3.10 is trading 1007.1% above its estimated GF Value™ of $0.28.
GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.
Key valuation signals for CTMX:
Equity-to-Asset: 0.89 (424% above median its 10-year median of 0.17)
GF Value™: $0.28 vs. price of $3.10 (1007.1% above fair value)
Industry Position: 30.9% above the Biotechnology median (#262 of 1416)
No single metric tells the full story. See the CTMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
36GF Score
Get the complete analysis for CTMX
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTMX has been successfully added to your 
